Literature DB >> 34507939

Resistant type 2 amiodarone-induced thyrotoxicosis responsive to cholestyramine as an adjunctive therapy.

Aisha Rummaan1, Maryam Maryam1, Awais Ali1, Snigdhendu Mandal1, Tamar Saeed2.   

Abstract

Amiodarone is a class 3 antiarrhythmic drug which may be associated with thyroid dysfunction. Amiodarone-induced thyrotoxicosis (AIT) is classified as type 1 (AIT 1; which may develop in the presence of latent autoimmune hyperthyroid condition) or type 2 (AIT 2; which develops in an apparently normal thyroid resulting from destructive thyroiditis). AIT 1 routinely requires treatment with thionamides, whereas AIT 2 is treated with steroids. Resistance to the conventional treatment of hyperthyroidism is not commonly found in clinical practice. This report discusses a case of AIT 2 resistant to conventional treatment. Despite being on high doses of carbimazole and steroids (prednisolone), the patient remained thyrotoxic. Cholestyramine, a bile salt sequestrant, was used as an adjunctive therapy resulting in significant clinical and biochemical improvement. The patient subsequently became euthyroid and is being followed up in endocrine clinic. © Royal College of Physicians 2021. All rights reserved.

Entities:  

Keywords:  AIT; amiodarone-induced thyrotoxicosis; cholestyramine; resistant thyrotoxicosis

Mesh:

Substances:

Year:  2021        PMID: 34507939      PMCID: PMC8439522          DOI: 10.7861/clinmed.2021-0482

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   5.410


  7 in total

1.  Treatment of hyperthyroidism with a combination of methimazole and cholestyramine.

Authors:  M Mercado; V Mendoza-Zubieta; R Bautista-Osorio; A L Espinoza-de los Monteros
Journal:  J Clin Endocrinol Metab       Date:  1996-09       Impact factor: 5.958

2.  2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction.

Authors:  Luigi Bartalena; Fausto Bogazzi; Luca Chiovato; Alicja Hubalewska-Dydejczyk; Thera P Links; Mark Vanderpump
Journal:  Eur Thyroid J       Date:  2018-02-14

3.  The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism.

Authors:  Wen-Chin Tsai; Dee Pei; Tso-Fu Wang; Du-An Wu; Jer-Chuan Li; Cheng Lian Wei; Chien-Hsing Lee; Sheng-Pyng Chen; Shi-Wen Kuo
Journal:  Clin Endocrinol (Oxf)       Date:  2005-05       Impact factor: 3.478

4.  Dramatic response to cholestyramine in a patient with Graves' disease resistant to conventional therapy.

Authors:  Arántzazu Sebastián-Ochoa; Miguel Quesada-Charneco; Diego Fernández-García; Rebeca Reyes-García; Pedro Rozas-Moreno; Fernando Escobar-Jiménez
Journal:  Thyroid       Date:  2008-10       Impact factor: 6.568

Review 5.  Amiodarone induced thyrotoxicosis: diagnostic and therapeutic strategies.

Authors:  Gustavo A Cardenas; José M Cabral; Camilo A Leslie
Journal:  Cleve Clin J Med       Date:  2003-07       Impact factor: 2.321

Review 6.  Management of amiodarone-induced thyrotoxicosis.

Authors:  Chinnadorai Rajeswaran; Rhidian John Shelton; Stephen George Gilbey
Journal:  Swiss Med Wkly       Date:  2003-11-22       Impact factor: 2.193

Review 7.  Role of Cholestyramine in Refractory Hyperthyroidism: A Case Report and Literature Review.

Authors:  Khaled A Alswat
Journal:  Am J Case Rep       Date:  2015-07-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.